| UHC Medicaid Medical & Drug | Sodium Hyaluronate – Community Plan Medical Benefit Drug Policy | 2026-10-01 |
| UHC Medicaid Medical & Drug | Surgery of the Foot – Community Plan Medical Policy | 2026-10-01 |
| UHC Medicaid Medical & Drug | Surgery of the Hip – Community Plan Medical Policy | 2026-10-01 |
| UHC Medicaid Medical & Drug | Surgery of the Shoulder – Community Plan Medical Policy | 2026-10-01 |
| UHC Medicaid Medical & Drug | Tzield® (Teplizumab-Mzwv) – Community Plan Medical Benefit Drug Policy | 2026-10-01 |
| UHC Medicaid Medical & Drug | Xolair® (Omalizumab) – Community Plan Medical Benefit Drug Policy | 2026-10-01 |
| UHC Medicaid Medical & Drug | Zolgensma® (Onasemnogene Abeparvovec-Xioi) – Community Plan Medical Benefit Drug Policy | 2026-10-01 |
| UHC Surest Medical and Drug | Maximum Dosage and Frequency – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-10-01 |
| UHC UMR Medical and Drug | Maximum Dosage and Frequency – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-10-01 |
| UHC Commercial Medical & Drug | Maximum Dosage and Frequency – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-10-01 |